New York GU Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies | Conference

PSMA-Targeted 177Lu-PSMA-617 Heads for Regulatory Approval in mCRPC
April 22, 2021

Scott T. Tagawa, MD, considers data for the novel PSMA-targeted radiopharmaceutical 177Lu-PSMA-617.

Expert Explores the Current Status of Radium-223 Use in Castration-Resistant Prostate Cancer
March 28, 2021

During a presentation at the 14th Annual New York GU Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Scott T. Tagawa, MD, reviewed important findings related to radium-223 and its use in patients with castration-resistant prostate cancer.

How To Implement Next-Generation Imaging Recommendations in Prostate Cancer Management
March 26, 2021

At the New York GU 14th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Phillip J. Koo, MD, discussed the recommendations issued for the early detection of metastatic prostate cancer using next-generation imaging.

Next-Generation Imaging May Lead to Change in Management of Prostate Cancer, Expert Says
March 16, 2021

The use of next-generation imaging, like PSMA PET, has been shown to be superior compared with conventional imaging and may become a homestay in prostate cancer care in the future.

Updated Standard Practice for Managing Patients with Non-Muscle-Invasive Bladder Cancer
March 13, 2021

Leonard G. Gomella, MD, FACS, detailed updated information regarding the standard of care and overall management of patients with non-muscle invasive bladder cancer at the 2021 New York GU 14th Annual Interdisciplinary Prostate Cancer Congress®.

Management of Upper Tract Urothelial Tumors With Conservative Management, Mitomycin Gel
March 12, 2021

Scott G. Hubosky, MD, of Jefferson University Hospitals, discussed methods of treating patients with upper tract urothelial carcinoma at the 2021 New York GU 14th Annual Interdisciplinary Prostate Cancer Congress®.